• Citer

A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

par Limentani, Steven S.A.;Disis, Mary;Awada, Ahmad ;Berlière, Martine;Amant, Frédéric;Levine, Ellis;Burny, Wivine ;Callegaro, Andrea;De Sousa Alves, Pedro Miguel;Louahed, Jamila;Brichard, Vincent ;Csampone, Mario;Lehmann, Frédéric ;Dorval, Thierry;Curigliano, Giuseppe;de Boer, Richard;Vogel, Charles;White, Shane;Bachelot, Thomas;Canon, Jean-Luc
Référence Breast cancer research and treatment, 156, 2, page (319-330)
Publication Publié, 2016

Article révisé par les pairs

• Détails
• Contenu

Titre:	A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Auteur:	Limentani, Steven S.A.; Disis, Mary; Awada, Ahmad; Berlière, Martine; Amant, Frédéric; Levine, Ellis; Burny, Wivine; Callegaro, Andrea; De Sousa Alves, Pedro Miguel; Louahed, Jamila; Brichard, Vincent; Csampone, Mario; Lehmann, Frédéric; Dorval, Thierry; Curigliano, Giuseppe; de Boer, Richard; Vogel, Charles; White, Shane; Bachelot, Thomas; Canon, Jean-Luc
Informations sur la publication:	Breast cancer research and treatment, 156, 2, page (319-330)
Statut de publication:	Publié, 2016
Sujet CREF:	Cancérologie
Mots-clés:	Cancer immunotherapeutic
	DHER2 protein
	HER2-overexpressing breast cancer
	Vaccine
Note générale:	SCOPUS: ar.j
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0167-6806
	info:doi/10.1007/s10549-016-3751-x
	info:scp/85007189742
	info:pmid/26993131